Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13048973 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL745198 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL14281986 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL5058152 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL14264965 | 1.00 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013676 | 0.97 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013639 | 0.97 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013675 | 0.97 | CCR2 (1.00) | CCR2KCNH2 | |
| SCHEMBL6013624 | 0.96 | CCR2 (0.95) | CCR2KCNH2 | |
| SCHEMBL6013623 | 0.96 | CCR2 (0.95) | CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076120-A1 | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders | MILLENNIUM PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1819694-A2 | SALTS OF N-[2-({3R)-1-[trans-4-HYDROXY-4-(6-METHOXYPYRIDIN-3-YL)-CYCLOHEXYL]PYRROLIDINE-3-YL}AMINO)-2-OXOETHYL]-3-(TRIFLUOROMETHYL)BENZAMIDE | Incyte Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006073592-A3 | SALTS OF N-[2-({3R)-1-[trans-4-HYDROXY-4-(6-METHOXYPYRIDIN-3-YL)-CYCLOHEXYL]PYRROLIDINE-3-YL}AMINO)-2-OXOETHYL]-3-(TRIFLUOROMETHYL)BENZAMIDE | INCYTE CORP (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006073592-A2 | SALTS OF N-[2-({3R)-1-[trans-4-HYDROXY-4-(6-METHOXYPYRIDIN-3-YL)-CYCLOHEXYL]PYRROLIDINE-3-YL}AMINO)-2-OXOETHYL]-3-(TRIFLUOROMETHYL)BENZAMIDE | INCYTE CORPORATION (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | INCYTE CORPORATION | 2006-05-25 | — | — | US | disclosed |
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | INCYTE CORPORATION | 2006-05-25 | — | — | US | disclosed |
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | INCYTE CORPORATION | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111404-A1 | Salts of N-[2-({(3R)-1-[trans-4-hydroxy-4-(6-methoxypyridin-3-yl)-cyclohexyl]pyrrolidin-3-yl}amino)-2-oxoethyl]-3-(trifluoromethyl)benzamide | CCR5, CCR2, ACKR3 | CCR2 2/4885KCNH2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.